Transcend Therapeutics is a New York–based biotechnology company founded in 2021 and incubated by AlleyCorp that develops next-generation psychoactive drugs for neuropsychiatric diseases. Its lead compound, methylone (TSND-201), is described as short-acting with mild psychological effects and may require less clinician time than other psychedelic compounds. The company positions TSND-201 as a potential adjunctive treatment to existing pharmacotherapies (for example, SSRIs) to better integrate into current psychiatric care. Transcend already has real-world data for TSND-201 demonstrating responses in patients with PTSD. The company plans to use new funding to launch multiple clinical trials, including a phase II study. Leadership includes founders and senior executives with clinical and drug-development track records, including co-founders Blake Mandell and Ben Kelmendi, and senior development and clinical leads Martin Stogniew and Amanda Jones.

Total raised

$40M

Funding rounds

1

Latest round

Series A

Latest activity

Feb 2023